Navigation Links
Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting

ABBOTT PARK, Ill., June 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) scientists and independent researchers will highlight the latest clinical trial data on four of Abbott's investigational oncology compounds at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 4-8 in Chicago. The presentations include data on inhibitors of VEGFR and PDGFR, PARP and bcl-2, and a humanized monoclonal antibody directed against CS1. Abbott's oncology pipeline currently includes nine new molecular entities in the clinic, targeting more than 15 different cancers and tumor types.

Meeting abstracts are available online at

"With more than 12 million cancer patients diagnosed globally each year, we are fighting one of the greatest battles in medicine," said John Leonard, M.D., senior vice president, pharmaceuticals, research and development, Abbott. "The varied nature of the disease requires a diverse approach that includes multiple disease targets in different tumor types, and this is exactly the development path that we have chosen."

Presentation Highlights

Abbott's oncology pipeline consists of several different approaches for a broad range of cancers and, by focusing on some of the most promising areas of cancer research, including bcl-2 and PARP inhibition, Abbott scientists are targeting the processes cancers need to survive in order to advance new treatments.

Abbott data being presented includes two oral presentations on elotuzumab, an antibody designed to bind to the CS1 glycoprotein, a highly expressed cell surface protein in multiple myeloma. Four separate studies of linifanib (ABT-869), which is being studied as an inhibitor of the VEGFR and PDGFR kinase pathways, in advanced renal cell cancer (RCC), advanced solid tumors, advanced hepatocellular carcinoma (HCC) and non small cell lung cancer (NSCLC), also will be presented.

Abbott will also present results from a Phase 2 study of navitoclax (ABT-263) in small-cell lung cancer (SCLC) and independent researchers will present five studies on veliparib (ABT-888), a PARP-inhibitor, including phase 2 data in breast cancer.

Presentations include:

Linifanib (ABT-869)

Phase 2 trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure; Tannir et al.

  • Abstract 4527; Poster Discussion; June 5, 2010; 2 p.m. - 6 p.m.; Location: E540a; Poster number: 8.
  • Discussion: 5 p.m.6 p.m. in EHall D2.

Linifanib treatment in patients with non small cell lung cancer (NSCLC); Phase 2 results; R. A. Soo, et al.

  • Abstract 7590; Poster Session; June 6, 2010; 8 a.m.12 p.m.; Location: S Hall A2; Poster number: 41A.

Linifanib phase 2 trial in patients with advanced hepatocellular carcinoma (HCC); H. C. Toh, et al.

  • Abstract 4038; Poster Session; June 6, 2010; 2 p.m. - 6 p.m.; Location: S Hall A2; Poster number: 18A.

Extended linifanib therapy in patients with advanced solid tumors in a Phase 1 trial; B.C. Goh et al.

  • Abstract 3040: Poster Session; June 7, 2010; 8 a.m. - 12 p.m.; Location: S Hall A2; Poster number: 13E.

Veliparib (ABT-888)

A Phase 2 Trial of veliparib (ABT-888) and temozolomide for metastatic breast cancer; S. J. Isakoff et al.

  • Abstract 1019; Poster Discussion; June 5, 2010; 8 a.m. - 12 p.m.; Location: E540b; Poster number: 8.
  • Discussion: 12 p.m.1 p.m. in E Hall D1.

Preliminary results of a Phase 1 trial of ABT-888, a Poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with Cyclophosphamide; A. Tan et al.

  • Abstract 3000; Clinical Science Symposium; June 5, 2010; 4:30 p.m. - 6 p.m.; Location: E Arie Crown Theater; Presentation time: 4:45 p.m.

A Phase 1 study of ABT-888 in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas; S. Kummar et al.

  • Abstract 2605; Poster Session; June 7, 2010; 8 a.m. - 12 p.m. Location: S Hall A2; Poster board number: 9C.

Targeting Fanconi Anemia (FA) repair pathway deficiency for treatment with PARP inhibitors; W. Zhao et al.

  • Abstract TPS168; Trials in Progress Poster Session; June 7, 2010; 8 a.m. - 12 p.m.; Location: S Hall A2; Poster number: 8.

Pharmacodynamic response in Phase 1 combination study of ABT-888 and Topotecan in adults with refractory solid tumors and lymphomas; J .Ji et al.

  • Abstract 2514; Oral Abstract Session; June 8, 2010; 9:30 a.m. - 12:30 p.m.; Location: E354a; Presentation time: 12 p.m.

Navitoclax (ABT-263)

A phase 2a study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC); C.M. Rudin, et al.

  • Abstract 7046: Poster Session; June 6, 2010; 8 a.m. - 12 p.m.; Location: S Hall A2; poster number: 21D.

Elotuzumab (HuLuc63)

Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase 1 study; A.J. Jakubowiak.

  • Abstract 1702; Novel Therapies for Myeloma, oral presentation; June 5, 2010; 4:30 p.m.6 p.m.; Location: E354a; Presentation time: 5:30 p.m.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study; S. Lonial.

  • Abstract 1703; Myeloma session, oral presentation; June 6, 9:30 a.m.12:30 p.m.; Location: Rm E354b; Presentation time: 12 p.m.

Abbott's Oncology Research

Abbott's current pharmaceutical oncology research is focused on developing more targeted, less toxic therapies that improve survival and quality of life for patients living with cancer. Abbott's pipeline addresses multiple phases of cancer progression and targets processes that cancers need to survive, including programmed cell death (apoptosis), new blood vessel formation (angiogenesis) and travel throughout the body (metastasis).

Kinase Inhibitors (linifanib) – Linifanib is an oral small molecule that provides both potent and specific inhibition of the VEGFR and PDGFR families. Inhibition of the appropriate kinases can suppress tumor growth by preventing the formation and spread of new blood vessels that supply the tumor with oxygen and nutrients, and by inhibiting key angiogenic signaling pathways. Linifanib is in Phase III clinical trials for hepatocellular carcinoma (HCC) and ongoing Phase II trials in renal cell cancer (RCC), solid tumors, non small cell lung cancer (NSCLC) and selected hematologic malignancies such as leukemia.

PARP Inhibitors (veliparib) – Veliparib is an oral PARP-inhibitor that was discovered and developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common DNA-damaging therapies like chemotherapy or radiation. Veliparib is currently being studied in more than a dozen cancers and tumor types, including Phase II studies in melanoma and breast cancer. Veliparib is also being studied in the I-SPY 2 breast cancer trial, led by the Foundation for the National Institutes of Health.

Bcl-2 Family Protein Inhibitors (navitoclax) – Navitoclax restores apoptosis or programmed cell death, a natural mechanism for the elimination of cancerous cells, by inhibiting the function of Bcl-2 proteins. Bcl-2 regulates apoptosis, as well as tumor formation and tumor growth, and can enable cancer cells to resistance to treatment. Navitoclax is in clinical trials for lymphomas and solid tumors, including small cell lung cancer. Additionally, preclinical data have shown that Bcl-2 family protein inhibitors have the potential to enhance the effects of chemotherapy and radiation used to treat other types of cancer, such as non-small cell lung cancer.

Elotuzumab (HuLuc63) – Elotuzumab is a humanized monoclonal antibody that binds to CS1, a cell-surface glycoprotein that is highly expressed on myeloma cells but minimally expressed on normal human cells. Abbott is developing elotuzumab for multiple myeloma in collaboration with Bristol-Myers Squibb Company.

Beyond pharmaceutical research, Abbott provides supportive care products and diagnostics related to oncology. The company offers a broad range of pharmaceutical and nutritional products to help people living with cancer, including Juven®, Ensure® and ProSure® to help maintain proper nutrition during and after cancer treatment.

Abbott is also leading developer of cancer diagnostics, including molecular tests based on PCR (polymerase chain reaction) and fluorescence in situ hybridization (FISH) technologies to aid clinicians in the selection of appropriate pharmacogenomic therapies. Abbott's FISH products deliver unsurpassed sensitivity for early diagnosis and monitoring of cancer, as well as the ability to identify patients who may benefit from appropriate therapies, helping to improve outcomes and extend patient survival.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
2. Abbotts Groundbreaking Bioresorbable Technology Continues to Demonstrate Exceptional Clinical Results
3. Abbotts Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves
4. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
5. Assegai Wins Big Settlement Against ABBOTTs Subsidiary
6. Abbott 2009 Global Citizenship Report Highlights Companys Progress in Redefining Responsibility
7. Abbott Chairman and CEO Miles D. White to Present at Sanford Bernstein Strategic Decisions Conference
8. Abbott Annual Meeting Highlights Continued Strong Performance in 2009; Sustained Growth in 2010
9. Abbott Completes Acquisition of Facet Biotech
10. Abbott Completes Acquisition of STARLIMS Technologies
11. Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
Post Your Comments:
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
(Date:11/30/2015)... , 1 décembre 2015 ... exposition et conférence d,Asie portant sur ... sur l,industrie manufacturière, se tiendra à ... 20 au 22 avril 2016. ... Photo - ...
(Date:11/30/2015)... PUNE, India , December 1, 2015 ... --> adds "Endometriosis - ... that provides an overview on therapeutic pipeline ... capabilities to create effective counter strategies to ... by identifying new targets and MOAs to ...
Breaking Medicine Technology:
(Date:12/1/2015)... HANGZHOU, China (PRWEB) , ... December 01, 2015 , ... ... will result in its largest order to date. , The order will be ... implant systems. Nurotron’s Venus Cochlear Implant System is an effective solution for children and ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Trust on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. ... the patient care experience, and propose exciting enhancements to the medical landscape. , ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... engine optimization companies, announced today that it has officially launched a sleek, mobile-ready ... SEO, explained that his company’s new website clearly outlines the benefits that its ...
(Date:11/30/2015)... NC (PRWEB) , ... November 30, 2015 , ... Trevor ... corporate support as they play for the chance to represent the United States. This ... the opportunity to be a part of their journey in addition to offering corporate ...
(Date:11/30/2015)... ... December 01, 2015 , ... The ... a 2015-2016 inductee into its VIP Woman of the Year Circle. She is ... leading networking organization exclusively for professional women, boasting 850,000 members and over 200 ...
Breaking Medicine News(10 mins):